Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07080385 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)
A Phase 2 study of Autosomal Dominant Hypocalcemia Type 1 (ADH1), sponsored by Calcilytix Therapeutics, Inc., a BridgeBio company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 5
- Study locations
NCT07080385 is a Phase 2 study of Autosomal Dominant Hypocalcemia Type 1 (ADH1) that is actively recruiting participants, run by Calcilytix Therapeutics, Inc., a BridgeBio company. The registered enrollment target is 28 participants. The trial reports 5 study locations across 4 states.
The verdict
NCT07080385, a Phase 2 study of Autosomal Dominant Hypocalcemia Type 1 (ADH1), is actively recruiting participants, sponsored by Calcilytix Therapeutics, Inc., a BridgeBio company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 5
- Study locations
Study Summary
The overall objective of this study is to evaluate the pharmacokinetics (PK), efficacy, and safety of encaleret in pediatric participants from birth to 17 years of age with ADH1.
Conditions Studied
Interventions
- DRUG Encaleret
Study Locations (5)
Other
- Royal London Hospital - London
- Royal Manchester Children's Hospital - Manchester
Connecticut
- Yale University - New Haven
Florida
- Nemours Children's Health - Jacksonville
Pennsylvania
- The Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2026-01-30 |
| Est. Completion | 2030-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07080385
The ClinicalTrials.gov registry entry for NCT07080385 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Calcilytix Therapeutics, Inc., a BridgeBio company, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Autosomal Dominant Hypocalcemia Type 1 (ADH1) appearing as the primary indexed condition, and to 1 intervention - of which Encaleret is the first listed.
NCT07080385 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Other, Connecticut, Florida.
Frequently Asked Questions
What is clinical trial NCT07080385 about?
NCT07080385 is a clinical study titled "Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)". The overall objective of this study is to evaluate the pharmacokinetics (PK), efficacy, and safety of encaleret in pediatric participants from birth to 17 years of age with ADH1.
What is the current status of trial NCT07080385?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2026-01-30. Estimated completion is 2030-12.
What conditions does trial NCT07080385 study?
This clinical trial studies the following conditions: Autosomal Dominant Hypocalcemia Type 1 (ADH1).
What interventions are being tested in trial NCT07080385?
The interventions under investigation include: Encaleret (DRUG).
Who is sponsoring clinical trial NCT07080385?
This trial is sponsored by Calcilytix Therapeutics, Inc., a BridgeBio company, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07080385 being conducted?
This trial has 5 study locations across Connecticut, Florida, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.